Home / Health / UK Approves ImmunityBio's Groundbreaking Bladder Cancer Treatment
UK Approves ImmunityBio's Groundbreaking Bladder Cancer Treatment
23 Jul
Summary
- UK regulator approves ImmunityBio's ANKTIVA for bladder cancer
- ANKTIVA is a first-in-class IL-15 agonist that activates immune cells
- Some patients maintained complete cancer response for over 47 months
In a significant milestone, ImmunityBio, Inc. (NASDAQ:IBRX) recently announced that the UK's Medicines and Healthcare products Regulatory Agency has approved its bladder cancer treatment ANKTIVA. This marks the first approval for the company outside of the United States.
ANKTIVA is a groundbreaking drug that works by activating and multiplying immune cells, specifically natural killer (NK) cells and T cells, to help the body fight cancer. Clinical studies have demonstrated impressive results, with some patients maintaining a complete response for over 47 months at the last review.
ImmunityBio is a biopharmaceutical company dedicated to developing innovative therapies and vaccines that harness the power of the immune system. The approval of ANKTIVA in the UK is a significant achievement that could pave the way for further global expansion of the company's cutting-edge cancer treatments.
